@article{ATM6314,
author = {Jonas Cicenas and Karthik Kalyan and Aleksandras Sorokinas and Edvinas Stankunas and Josh Levy and Ingrida Meskinyte and Vaidotas Stankevicius and Algirdas Kaupinis and Mindaugas Valius},
title = {Roscovitine in cancer and other diseases},
journal = {Annals of Translational Medicine},
volume = {3},
number = {10},
year = {2015},
keywords = {},
abstract = {Roscovitine [CY-202, (R)-Roscovitine, Seliciclib] is a small molecule that inhibits cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a broad-range purine inhibitor, which inhibits CDK1, CDK2, CDK5 and CDK7, but is a poor inhibitor for CDK4 and CDK6. Roscovitine is widely used as a biological tool in cell cycle, cancer, apoptosis and neurobiology studies. Moreover, it is currently evaluated as a potential drug to treat cancers, neurodegenerative diseases, inflammation, viral infections, polycystic kidney disease and glomerulonephritis. This review focuses on the use of roscovitine in the disease model as well as clinical model research.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/6314}
}